The p53 gene was analyzed in tumor specimens obtained from 52 patients with various types of carcinoma of the thyroid gland by a combined molecular and immunocytochemical approach. The histologic types included 37 well-differentiated papillary and follicular carcinomas, 8 poorly differentiated, and 7 undifferentiated carcinomas. The p53 gene was shown to be unaffected in all differentiated tumors by single-strand conformation polymorphism analysis. However, in two out of eight (25%) of poorly differentiated carcinomas and five out of seven (71%) undifferentiated carcinomas, p53 mutations were identified and subsequently characterized by DNA sequencing. One undifferentiated carcinoma displayed two areas with varying degrees of differentiation. The comparative analysis of the p53 gene, in both the more and the less differentiated area of this tumor, clearly showed that the p53 mutation was confined to the latter component of the tumor specimen. These results indicate that mutations of the p53 gene are associated with the most aggressive histologic types of thyroid tumors, such as the undifferentiated carcinoma and, to a certain extent, the poorly differentiated carcinoma, and that the alterations of this gene represent a late genetic event in human thyroid carcinogenesis.
R Donghi, A Longoni, S Pilotti, P Michieli, G Della Porta, M A Pierotti
Title and authors | Publication | Year |
---|---|---|
Genomic and Transcriptomic Hallmarks of Poorly-Differentiated and Anaplastic Thyroid Cancers
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A. Knauf, Ronak Shah, Snjezana Dogan, Julio Ricarte-Filho, Gnana P. Krishnamoorthy, Bin Xu, Nikolaus Schultz, Michael Berger, Chris Sander, Barry Taylor, Ronald Ghossein, Ian Ganly, James Fagin |
Journal of Clinical Investigation | 2016 |
Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer
S Narayanan, AD Colevas |
Current Treatment Options in Oncology | 2016 |
Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation
Y Shetzer, A Molchadsky, V Rotter |
Cold Spring Harbor Perspectives in Medicine | 2016 |
Expression of glutamine metabolism-related proteins in thyroid cancer
HM Kim, YK Lee, JS Koo |
Oncotarget | 2016 |
Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer
S Latteyer, V Tiedje, K König, S Ting, LC Heukamp, L Meder, KW Schmid, D Führer, LC Moeller |
Endocrine | 2016 |
Molecular genetics of thyroid cancer
M Rebaї, A Rebaї |
Genetics Research | 2016 |
Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer
L Zhang, M Boufraqech, R Lake, E Kebebew |
Oncotarget | 2016 |
Nodular thyroid disease in the elderly: novel molecular approaches for the diagnosis of malignancy
S Sorrenti, E Baldini, F Tartaglia, A Catania, S Arcieri, D Pironi, PG Calò, A Filippini, S Ulisse |
Aging clinical and experimental research | 2016 |
Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer
S Latteyer, V Tiedje, K König, S Ting, LC Heukamp, L Meder, KW Schmid, D Führer, LC Moeller |
Endocrine | 2016 |
Next-generation sequence detects ARAP3 as a novel oncogene in papillary thyroid carcinoma
QX Wang, ED Chen, YF Cai, YL Zhou, ZC Zheng, YH Wang, YX Jin, WX Jin, XH Zhang, OC Wang |
OncoTargets and therapy | 2016 |
Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma
J Lu, S Guan, Y Zhao, Y Yu, Y Wang, Y Shi, X Mao, KL Yang, W Sun, X Xu, JS Yi, T Yang, J Yang, JG Nuchtern |
Oncotarget | 2016 |